Evidence map›Paper›PMID 41737720›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

Web-based LAS-FNAME and blood biomarkers in autosomal dominant Alzheimer's disease.

Christopher Gonzalez Corona, Paula Ospina Lopera, Meredith C Rowe, Clara Vila-Castelar, Averi Giudicessi, Vincent Malotaux, Bing He, Catarina Tristão-Pereira, Jairo E Martinez, Laura Osorio Asprilla and 7 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Christopher Gonzalez CoronaDepartment of Psychiatry Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Paula Ospina LoperaGrupo de Neurociencias de Antioquia Facultad de Medicina, Universidad de Antioquia Medellín Colombia.
Meredith C RoweDepartment of Psychiatry Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Clara Vila-CastelarDepartment of Psychiatry Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Averi GiudicessiDepartment of Psychiatry Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Vincent MalotauxDepartment of Psychiatry Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Bing HeDepartment of Psychiatry Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Catarina Tristão-PereiraDepartment of Psychiatry Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Jairo E MartinezDepartment of Psychiatry Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Laura Osorio AsprillaGrupo de Neurociencias de Antioquia Facultad de Medicina, Universidad de Antioquia Medellín Colombia.
María Susana Ramírez GallegoGrupo de Neurociencias de Antioquia Facultad de Medicina, Universidad de Antioquia Medellín Colombia.
Diana Paola Alzate EcheverriGrupo de Neurociencias de Antioquia Facultad de Medicina, Universidad de Antioquia Medellín Colombia.
Laura SernaGrupo de Neurociencias de Antioquia Facultad de Medicina, Universidad de Antioquia Medellín Colombia.
Nicholas J AshtonDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology the Sahlgrenska Academy at the University of Gothenburg, Wallinsgatan Mölndal Sweeden.
A Claudio CuelloDepartment of Pharmacology and Therapeutics McGill University Montreal Quebec Canada.
David AguillonGrupo de Neurociencias de Antioquia Facultad de Medicina, Universidad de Antioquia Medellín Colombia.
Yakeel T QuirozDepartment of Psychiatry Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.ORCID https://orcid.org/0000-0001-9714-8244

Funding

Resilience to Cognitive Decline and Resistance to Alzheimer's Disease and Related Neurodegenerative Diseases in Individuals from Colombia with Autosomal Dominant DementiasRM1NS132996 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI AGUILLON, DAVID FERNANDO, ARBOLEDA-VELASQUEZ, JOSEPH · 2023 to 2023
$3.8M
Nerve Growth (NGF) Factor Metabolic Dysfunction as a Marker of Cognitive Decline in Autosomal Dominant Alzheimer's DiseaseR01AG077627 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI David Fernando Aguillon, A CLAUDIO CUELLO · 2025 to 2026
$1.3M
NIA NIH HHS R01 AG077627NINDS NIH HHS RM1 NS132996
6 · The paper itself

Abstract

introductionThis study examined whether performance on the web-based Latin American Spanish Face-Name Associative Memory Exam (LAS-FNAME), an associative memory test, is associated with plasma biomarkers in autosomal dominant Alzheimer's disease (ADAD).

methodsOne hundred sixty-one members from the Colombian kindred with presenilin-1 (

resultsCarriers had lower LAS-FNAME performance (P < 0.001) and higher p-tau217 (P < 0.001), NfL (P = 0.013), and GFAP (P < 0.001) levels than non-carriers. Higher p-tau217, NfL, and GFAP were associated with worse LAS-FNAME performance, controlling for age, sex, and education. DISCUSSION: The web-based LAS-FNAME is a promising tool for detecting early memory decline in AD, warranting future studies to evaluate its longitudinal utility. Highlights: The web-based Latin American Spanish Face-Name Associative Memory Exam (LAS-FNAME) detects memory decline in presenilin 1 (

Indexed as

alzheimer's diseaseassociative memoryautosomal dominant alzheimer's diseaseneuropsychology

Identifiers

PMID41737720
PMCPMC12927991

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.